Jay B. Lichter Ph.D.
Net Worth
Last updated:
What is Jay B. Lichter Ph.D. net worth?
The estimated net worth of Dr. Jay B. Lichter Ph.D. is at least $3,147,630 as of 3 Mar 2021. He owns shares worth $12,527 as insider, has earned $2,347,283 from insider trading and has received compensation worth at least $787,820 in Otonomy, Inc..
What is the salary of Jay B. Lichter Ph.D.?
Dr. Jay B. Lichter Ph.D. salary is $71,620 per year as Co-Founder & Independent Chairman in Otonomy, Inc..
How old is Jay B. Lichter Ph.D.?
Dr. Jay B. Lichter Ph.D. is 63 years old, born in 1962.
What stocks does Jay B. Lichter Ph.D. currently own?
As insider, Dr. Jay B. Lichter Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Otonomy, Inc. (OTIC) | Co-Founder & Independent Chairman | 113,935 | $0.11 | $12,527 |
What does Otonomy, Inc. do?
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Jay B. Lichter Ph.D. insider trading
Otonomy, Inc.
Dr. Jay B. Lichter Ph.D. has made 8 insider trades between 2014-2021, according to the Form 4 filled with the SEC. Most recently he sold 207,245 units of OTIC stock on 3 Mar 2021.
The largest trade he's ever made was exercising 503,135 units of OTIC stock on 24 Feb 2021. As of 3 Mar 2021 he still owns at least 113,935 units of OTIC stock.
Otonomy key executives
Otonomy, Inc. executives and other stock owners filed with the SEC:
- Dr. David Allen Weber (65) Pres, Chief Executive Officer & Director
- Dr. Jay B. Lichter Ph.D. (63) Co-Founder & Independent Chairman
- Mr. Paul E. Cayer (63) Chief Financial & Bus. Officer
- Mr. Robert Michael Savel II (57) Chief Technical Officer